{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093932","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.375472+00:00","generated_at":"2026-05-31T11:05:23.309853+00:00","sec_items":["2.02","3.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"IN8bio receives Nasdaq minimum bid price deficiency notice; Q2 net loss $8.6M, cash $10.2M","bullets":["Nasdaq notified IN8bio on Aug 6, 2024 that bid price closed below $1.00 for 31 consecutive days; 180-day compliance period to Feb 3, 2025.","Q2 2024 net loss of $8.6M ($0.19 per share) vs net loss of $7.7M ($0.27) in Q2 2023.","Cash and cash equivalents totaled $10.2M as of June 30, 2024, down from $21.3M at Dec 31, 2023.","Phase 1 INB-100 data: 100% 1-year complete remission in evaluable patients; two patients relapse-free over 3.5 years.","Phase 1 INB-200: 92% of GBM patients exceeded median PFS of 7 months; no cell therapy-related toxicities observed."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093932","json":"https://secwatch.observer/filing/0000950170-24-093932.json","markdown":"https://secwatch.observer/filing/0000950170-24-093932.md","text":"https://secwatch.observer/filing/0000950170-24-093932.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000095017024093932/0000950170-24-093932-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000095017024093932/inab-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:05:23.309853+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}